Matti Lehtinen

Author PubWeight™ 105.66‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005 9.67
2 Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004 4.10
3 Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2011 3.98
4 Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010 3.41
5 Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006 2.78
6 Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007 2.64
7 A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009 2.42
8 Seroepidemiology of the human polyomaviruses. J Gen Virol 2003 2.32
9 Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006 2.10
10 HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008 2.09
11 The effects of storage time and sampling season on the stability of serum 25-hydroxy vitamin D and androstenedione. Nutr Cancer 2010 1.86
12 Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol 2012 1.70
13 Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009 1.66
14 Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007 1.63
15 Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol 2008 1.62
16 Anticipated acceptance of HPV vaccination at the baseline of implementation: a survey of parental and adolescent knowledge and attitudes in Finland. J Adolesc Health 2007 1.60
17 Nordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. Acta Oncol 2007 1.51
18 A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer 2002 1.43
19 Proximity of first sexual intercourse to menarche and risk of high-grade cervical disease. J Infect Dis 2012 1.39
20 Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 2003 1.20
21 Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles. J Gen Virol 2005 1.15
22 Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009 1.15
23 Introducing human papillomavirus vaccines - questions remain. Ann Med 2008 1.14
24 High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004 1.12
25 Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population--a candidate gene approach. Int J Cancer 2009 1.11
26 Three factor eating questionnaire-R18 as a measure of cognitive restraint, uncontrolled eating and emotional eating in a sample of young Finnish females. Int J Behav Nutr Phys Act 2009 1.09
27 Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer 2011 1.08
28 Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up. Int J Cancer 2012 1.04
29 Determinants of maternal sex steroids during the first half of pregnancy. Obstet Gynecol 2011 1.01
30 Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Int J Cancer 2012 1.01
31 Circulating estrogens and progesterone during primiparous pregnancies and risk of maternal breast cancer. Int J Cancer 2011 1.00
32 Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int J Cancer 2010 1.00
33 Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis 2013 1.00
34 Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study. Cancer Epidemiol Biomarkers Prev 2005 0.99
35 Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection. Scand J Infect Dis 2008 0.98
36 Independent and joint effects of serum 25-hydroxyvitamin D and calcium on ovarian cancer risk: a prospective nested case-control study. Eur J Cancer 2010 0.95
37 Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect Dis 2010 0.94
38 Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer. Cancer Epidemiol Biomarkers Prev 2011 0.93
39 Serum antibody response to the heat shock protein 60 of Chlamydia trachomatis in women with developing cervical cancer. Am J Obstet Gynecol 2003 0.93
40 Effect of long-term storage on hormone measurements in samples from pregnant women: the experience of the Finnish Maternity Cohort. Acta Oncol 2007 0.93
41 Chlamydial antibodies and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2005 0.92
42 Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study. Int J Cancer 2002 0.90
43 Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. Scand J Infect Dis 2010 0.90
44 In vivo and in vitro intragenomic rearrangement of TT viruses. J Virol 2007 0.90
45 Tobacco smoking and chewing as risk factors for multiple human papillomavirus infections and cervical squamous intraepithelial lesions in two countries (Côte d'Ivoire and Finland) with different tobacco exposure. Cancer Causes Control 2008 0.90
46 Serum 25-hydroxyvitamin D at pregnancy and risk of breast cancer in a prospective study. Eur J Cancer 2010 0.89
47 Chlamydial heat shock protein 60--specific T cells in inflamed salpingeal tissue. Fertil Steril 2002 0.89
48 Endogenous steroid hormone levels in early pregnancy and risk of testicular cancer in the offspring: a nested case-referent study. Int J Cancer 2009 0.88
49 Maternal Epstein-Barr virus and cytomegalovirus infections and risk of testicular cancer in the offspring: a nested case-control study. APMIS 2008 0.88
50 Chlamydia pneumoniae infection and the risk of female early-onset lung cancer. Int J Cancer 2003 0.88
51 Human chorionic gonadotropin in pregnancy and maternal risk of breast cancer. Cancer Res 2010 0.86
52 A discrepancy of Chlamydia trachomatis incidence and prevalence trends in Finland 1983-2003. BMC Infect Dis 2008 0.86
53 Activation of maternal Epstein-Barr virus infection and risk of acute leukemia in the offspring. Am J Epidemiol 2006 0.86
54 High prevalence of HPV among female students in Finland. Scand J Infect Dis 2005 0.86
55 Just implementation of human papillomavirus vaccination. J Med Ethics 2011 0.85
56 Lack of association between human papillomavirus type 16 and 18 infections and female lung cancer. Cancer Epidemiol Biomarkers Prev 2010 0.85
57 Serum 25-hydroxyvitamin D and the risk of ovarian cancer. Eur J Cancer 2009 0.83
58 Divergent coverage, frequency and costs of organised and opportunistic Pap testing in Finland. Int J Cancer 2013 0.82
59 Circulating sex steroids during pregnancy and maternal risk of non-epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2010 0.82
60 The ethics of implementing human papillomavirus vaccination in developed countries. Med Health Care Philos 2011 0.82
61 Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan women. Scand J Infect Dis 2010 0.82
62 Phylogenetically diverse TT virus viremia among pregnant women. Virology 2012 0.82
63 Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise. J Med Econ 2010 0.82
64 Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach. PLoS One 2013 0.81
65 Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries. Infect Dis Obstet Gynecol 2011 0.81
66 Maternal smoking during pregnancy and testicular cancer in the sons: a nested case-control study and a meta-analysis. Eur J Cancer 2009 0.81
67 Order of HPV/Chlamydia infections and cervical high-grade precancer risk: a case-cohort study. Int J Cancer 2013 0.81
68 Lack of significant effects of Chlamydia trachomatis infection on cervical cancer risk in a nested case-control study in North-East Thailand. Asian Pac J Cancer Prev 2014 0.81
69 Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence. BMC Res Notes 2011 0.80
70 Impact of HPV vaccination on young women's quality of life - a five year follow-up study. Eur J Contracept Reprod Health Care 2010 0.80
71 No risk of maternal EBV infection for childhood leukemia. Cancer Epidemiol Biomarkers Prev 2009 0.79
72 Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women. Int J Cancer 2009 0.79
73 Maternal human polyomavirus infection and risk of neuroblastoma in the child. Int J Cancer 2005 0.79
74 Impact of HPV16/18 vaccination on quality of life: a pilot study. Eur J Contracept Reprod Health Care 2013 0.78
75 The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland. Int J Cancer 2013 0.78
76 Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. Emerg Infect Dis 2016 0.78
77 LINDA - a solution-focused low-intensity intervention aimed at improving health behaviors of young females: a cluster-randomized controlled trial. BMC Public Health 2013 0.77
78 Association between Epstein-Barr virus infection and risk for development of pregnancy-associated breast cancer: joint effect with vitamin D? Eur J Cancer 2010 0.77
79 Population fraction of cervical neoplasia attributable to high-risk human papillomaviruses. Future Oncol 2010 0.77
80 Circulating insulin-like growth factor-I in pregnancy and maternal risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2011 0.76
81 Association of serum 25-hydroxyvitamin D (25-OHD) concentrations with maternal sex steroids and IGF-1 hormones during pregnancy. Cancer Causes Control 2011 0.76
82 Impact of human papillomavirus vaccination depends on effective vaccination strategy. Int J Cancer 2009 0.76
83 Women and vaccinations: From smallpox to the future, a tribute to a partnership benefiting humanity for over 200 years. Hum Vaccin 2009 0.76
84 Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot study. BMC Res Notes 2014 0.75
85 Prophylactic human papillomavirus vaccine. Womens Health (Lond Engl) 2006 0.75
86 Geographic distribution of cervical cancer-associated human leucocyte antigens and cervical cancer incidence in Finland. Int J STD AIDS 2007 0.75
87 First-generation vaccines against human papillomavirus. Womens Health (Lond Engl) 2005 0.75
88 Preventing common sexually transmitted infections in adolescents: time for rethinking. Eur J Contracept Reprod Health Care 2006 0.75
89 Strengthening prevention programs to eliminate cervical cancer in the Nordic countries. Acta Obstet Gynecol Scand 2008 0.75
90 An increasing proportion of reported Chlamydia trachomatis infections are repeated diagnoses. Sex Transm Dis 2012 0.75
91 Population-Based Study of Prediagnostic Antibodies to Chlamydia trachomatis in Relation to Adverse Pregnancy Outcome. Sex Transm Dis 2016 0.75
92 Insulin-like growth factor-I and C-reactive protein during pregnancy and maternal risk of non-epithelial ovarian cancer: a nested case-control study. Cancer Causes Control 2011 0.75
93 Changes over time in the Chlamydia trachomatis serotype distribution in Finnish women. Scand J Infect Dis 2014 0.75
94 [Not Available]. Duodecim 2006 0.75